Earnings ·
Lexeo Therapeutics reported second quarter 2026 financial results, posting a net loss of $25.9 million or $0.30 per…
LXEOLexeo Therapeutics, Inc.
Lexeo Therapeutics reported second quarter 2026 financial results, posting a net loss of $25.9 million or $0.30 per share, compared to a $26.1 million loss in the prior year period. Research and development expenses increased to $19.0 million from $14.7 million, while general and administrative expenses decreased significantly to $9.0 million from $16.0 million. The company ended the quarter with $234.2 million in cash, cash equivalents, and investments, providing an operational runway into 2028. Clinically, Lexeo initiated the SUNRISE-FA 2 pivotal trial for its lead candidate LX2006 in Friedreich ataxia cardiomyopathy, enrolling the first patient in June 2027, with topline data expected in the second half of 2027. Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim clinical data. Lexeo Therapeutics is a clinical-stage genetic medicine company developing novel treatments for cardiovascular diseases.